Annals of Oncology, 0923-7534

Journal

Related Publications
  1. Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study

    van der Meulen, M., Bakunina, K., Nijland, M., Minnema, M. C., Cull, G., Stevens, W. B. C., Baars, J. W., Mason, K. D., Beeker, A., Beijert, M., Taphoorn, M. J. B., van den Bent, M. J., Issa, S., Doorduijn, J. K., Bromberg, J. E. C. & Dirven, L., 1-Aug-2020, In : Annals of Oncology. 31, 8, p. 1046-1055 10 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  2. The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies

    Cirkel, G. A., Weeber, F., Bins, S., Gadellaa-van Hooijdonk, C. G. M., van Werkhoven, E., Willems, S. M., van Stralen, M., Veldhuis, W. B., Ubink, I., Steeghs, N., de Jonge, M. J., Langenberg, M. H. G., Schellens, J. H. M., Sleijfer, S., Lolkema, M. P. & Voest, E. E., Aug-2016, In : Annals of Oncology. 27, 8, p. 1638-1643 6 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study

    Goey, K. K. H., Elias, S. G., van Tinteren, H., Laclé, M. M., Willems, S. M., Offerhaus, G. J. A., de Leng, W. W. J., Strengman, E., Ten Tije, A. J., Creemers, G-J. M., van der Velden, A., de Jongh, F. E., Erdkamp, F. L. G., Tanis, B. C., Punt, C. J. A. & Koopman, M., 1-Sep-2017, In : Annals of Oncology. 28, 9, p. 2128-2134 7 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. 89Zr-labeled anti-PD-L1 CX-072 PET imaging in human xenograft and syngeneic tumors

    Giesen, D., Broer, L. N., Lub-De Hooge, M. N., Popova, I., Howng, B., Vasiljeva, O., de Vries, E. G. E. & Pool, M., Feb-2019, In : Annals of Oncology. 30 , Suppl 1, p. i4 1 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  5. Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors

    Dumoulin, D., de Goeje, P., Poncin, M., Bezemer, K., Groen, H. J. M., Smit, E. F., Dingemans, A-M. C., Kunert, A., Hendriks, R. & Aerts, J. G., Apr-2019, In : Annals of Oncology. 30 , Suppl 2, p. ii7 1 p.

    Research output: Contribution to journalMeeting AbstractAcademic

View all (193) »

ID: 13479495